{"id":349268,"date":"2025-08-25T16:51:18","date_gmt":"2025-08-25T16:51:18","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-protagonist-therapeutics\/"},"modified":"2025-08-25T16:51:18","modified_gmt":"2025-08-25T16:51:18","slug":"how-to-buy-protagonist-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/","title":{"rendered":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-349268","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Protagonist Therapeutics, Inc. (PTGX) hisselerini g\u00fcncel fiyat\u0131 $57.48 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu biyoteknoloji hissesi i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Protagonist Therapeutics, Inc. (PTGX) hisselerini g\u00fcncel fiyat\u0131 $57.48 ile nas\u0131l alaca\u011f\u0131n\u0131z\u0131 \u00f6\u011frenin. Bu biyoteknoloji hissesi i\u00e7in yat\u0131r\u0131m stratejilerini, riskleri ve b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Keskin biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Protagonist Therapeutics (PTGX), \u015fu anda ila\u00e7 sekt\u00f6r\u00fcndeki en heyecan verici f\u0131rsatlardan biridir. FDA onay\u0131na yakla\u015fan iki \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7 ve 2028'e kadar uzanan nakit rezervi ile bu \u015firket, size \u00f6nemli getiriler sa\u011flayabilir. Bu yat\u0131r\u0131m\u0131 sizin i\u00e7in nas\u0131l i\u015fe yarar hale getirece\u011finizi birlikte ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Protagonist Therapeutics (PTGX), \u015fu anda ila\u00e7 sekt\u00f6r\u00fcndeki en heyecan verici f\u0131rsatlardan biridir. FDA onay\u0131na yakla\u015fan iki \u00e7\u0131\u011f\u0131r a\u00e7an ila\u00e7 ve 2028'e kadar uzanan nakit rezervi ile bu \u015firket, size \u00f6nemli getiriler sa\u011flayabilir. Bu yat\u0131r\u0131m\u0131 sizin i\u00e7in nas\u0131l i\u015fe yarar hale getirece\u011finizi birlikte ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Giri\u015f Stratejisi<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Protagonist Therapeutics (PTGX) hisseleri <strong>hisse ba\u015f\u0131na $57.48<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Hisse senedi inan\u0131lmaz bir yolculuk ge\u00e7irdi, Mart 2025'te t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi olan $59.76'ya ula\u015ft\u0131 ve y\u0131l boyunca g\u00fc\u00e7l\u00fc momentumunu korudu.<\/p> <p><strong>Takviminize not edin: 6 Kas\u0131m 2025<\/strong>, PTGX yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu a\u00e7\u0131klamalar hisse senedini \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirdi.<\/p> <h3>FDA Kararlar\u0131n\u0131n PTGX Hisselerine Etkisi<\/h3> <p>Son d\u00fczenleyici tetikleyicilere bakt\u0131\u011f\u0131m\u0131zda net bir desen g\u00f6r\u00fcyoruz:<\/p> <ul> <li><strong>Temmuz 2025<\/strong>: \u0130cotrokinra i\u00e7in NDA ba\u015fvurusu - sonraki hafta hisse %8 artt\u0131<\/li> <li><strong>Haziran 2025<\/strong>: Rusfertide Faz 3 verilerinin ASCO sunumu - an\u0131nda %12 y\u00fckseli\u015f<\/li> <li><strong>Mart 2025<\/strong>: \u00c7\u0131\u011f\u0131r A\u00e7an Terapi tan\u0131m\u0131 - iki hafta i\u00e7inde %15 s\u0131\u00e7rama<\/li> <li><strong>\u015eubat 2025<\/strong>: 4. \u00e7eyrek kazan\u00e7lar\u0131 beklentilerin \u00fczerinde - istikrarl\u0131 %6 de\u011fer art\u0131\u015f\u0131<\/li> <li><strong>Kas\u0131m 2024<\/strong>: Takeda ortakl\u0131k duyurusu - tek g\u00fcnde %18 s\u0131\u00e7rama<\/li> <li><strong>A\u011fustos 2024<\/strong>: Pozitif Faz 2b sonu\u00e7lar\u0131 - ay boyunca kademeli %22 art\u0131\u015f<\/li> <\/ul> <p>Desen a\u00e7\u0131k: d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 PTGX hissedarlar\u0131 i\u00e7in patlay\u0131c\u0131 b\u00fcy\u00fcme f\u0131rsatlar\u0131 yarat\u0131yor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h2> <p>Protagonist hisseleri son alt\u0131 ayda etkileyici getiriler sa\u011flad\u0131:<\/p> <p><strong>Mart<\/strong>: $59.76 (\u00c7\u0131\u011f\u0131r A\u00e7an Terapi haberi sonras\u0131 t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi)<br\/> <strong>Nisan<\/strong>: $54.20 (kar realizasyonu d\u00f6nemi)<br\/> <strong>May\u0131s<\/strong>: $51.80 (piyasa konsolidasyonu)<br\/> <strong>Haziran<\/strong>: $58.90 (ASCO veri a\u00e7\u0131klamas\u0131 sonras\u0131 y\u00fckseli\u015f)<br\/> <strong>Temmuz<\/strong>: $56.40 (NDA ba\u015fvurusu sonras\u0131 so\u011fuma)<br\/> <strong>A\u011fustos<\/strong>: $57.48 (mevcut istikrar)<\/p> <p>Bu, Mart zirvesinden <strong>% -3.8<\/strong> d\u00fc\u015f\u00fc\u015f\u00fc temsil ediyor ancak tipik biyoteknoloji volatilitesi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda hala dikkat \u00e7ekici bir dayan\u0131kl\u0131l\u0131k g\u00f6steriyor. Hisse senedi d\u00fczeltmelerden toparlanma yetene\u011fini kan\u0131tlad\u0131 ve bu da hem k\u0131sa vadeli yat\u0131r\u0131mc\u0131lar hem de uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in cazip hale getiriyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik deneme ilerlemesine dayanarak, beklenenler \u015funlar:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: $65-75 aral\u0131\u011f\u0131 (FDA kararlar\u0131na ba\u011fl\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br\/> <strong>2026<\/strong>: $85-100 (potansiyel ticarile\u015fmenin ilk tam y\u0131l\u0131)<br\/> <strong>2028<\/strong>: $120-150 (her iki ilac\u0131n da yerle\u015fik piyasa varl\u0131\u011f\u0131)<br\/> <strong>2030<\/strong>: $180-220+ (pipeline geni\u015flemesi ve uluslararas\u0131 b\u00fcy\u00fcme)<\/p> <p>Karar net: PTGX \u015fu anda biyoteknoloji alan\u0131ndaki en cazip al\u0131m f\u0131rsatlar\u0131ndan biri. \u0130ki potansiyel blockbuster ilac\u0131n onaya yakla\u015fmas\u0131 ve nakit pozisyonunun seyrelme riskini ortadan kald\u0131rmas\u0131, k\u0131sa vadeli volatilitenin \u00e7ok \u00f6tesinde bir yukar\u0131 potansiyel sunuyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>FDA reddi riski<\/strong>: Her iki ila\u00e7 da d\u00fczenleyici engellerle kar\u015f\u0131la\u015fabilir<\/li> <li><strong>Klinik deneme aksakl\u0131klar\u0131<\/strong>: Beklenmedik g\u00fcvenlik sorunlar\u0131 ortaya \u00e7\u0131kabilir<\/li> <li><strong>Rekabet<\/strong>: Benzer tedaviler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li> <li><strong>Piyasa volatilitesi<\/strong>: Biyoteknoloji sekt\u00f6r\u00fc dramatik dalgalanmalarla bilinir<\/li> <li><strong>Uygulama riski<\/strong>: Onay sonras\u0131 ticarile\u015ftirme zorluklar\u0131<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>\u00c7ift NDA s\u00fcreci<\/strong>: \u0130ki ila\u00e7 ayn\u0131 anda onaya yakla\u015f\u0131yor<\/li> <li><strong>\u00c7\u0131\u011f\u0131r A\u00e7an stat\u00fc<\/strong>: Rusfertide \u00f6zel FDA tan\u0131m\u0131na sahip<\/li> <li><strong>Nakit g\u00fcvenli\u011fi<\/strong>: 673 milyon dolar finansman endi\u015felerini ortadan kald\u0131r\u0131yor<\/li> <li><strong>B\u00fcy\u00fck ila\u00e7 ortakl\u0131klar\u0131<\/strong>: Takeda ve J&amp;J onay sa\u011fl\u0131yor<\/li> <li><strong>Piyasa talebi<\/strong>: Her iki durum da kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 temsil ediyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Rahat oldu\u011funuz bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n - hatta 5-10 hisse<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: $55 alt\u0131ndaki d\u00fc\u015f\u00fc\u015flerde pozisyonunuza ekleyin<\/li> <li><strong>Uyar\u0131lar kurun<\/strong>: 6 Kas\u0131m kazan\u00e7lar\u0131n\u0131 ve FDA duyurular\u0131n\u0131 takip edin<\/li> <li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu 2-3 y\u0131ll\u0131k bir yat\u0131r\u0131m hikayesi, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li> <li><strong>Esprili yakla\u015f\u0131m<\/strong>: \"PTGX ticareti bir t\u0131bbi drama izlemek gibi - bolca gerilim var ama sezon finali muhte\u015fem olabilir!\"<\/li> <\/ol> <h2>\u2705 Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>PTGX'i detayl\u0131ca ara\u015ft\u0131r\u0131n<\/td><td>\u015eirketin pipeline'\u0131n\u0131 ve risklerini anlay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015finizi verin<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 takip edin<\/td><td>Anahtar seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, yeni ba\u015flayanlar i\u00e7in ideal k\u0131lan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece $5 minimum depozito<\/strong> - \u00d6\u011frenirken neredeyse risksiz ba\u015flayabilirsiniz<\/li> <li><strong>\u015eim\u015fek h\u0131z\u0131nda do\u011frulama<\/strong> - Tek bir belge y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong> - Karlar\u0131n\u0131z\u0131 birden fazla \u00f6deme y\u00f6ntemiyle \u00e7ekin<\/li> <li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> - Hisse senedi ticaretine yeni ba\u015flayanlar i\u00e7in m\u00fckemmel<\/li> <\/ul> <p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, Protagonist Therapeutics ile stratejileri test etmek ve daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce denemek i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Protagonist: Biyoteknolojinin Y\u00fckselen Y\u0131ld\u0131z\u0131<\/h2> <p>Protagonist Therapeutics, en heyecan verici orta \u00f6l\u00e7ekli biyoteknoloji \u015firketlerinden biri olarak konumland\u0131. \u0130ki yeni peptid terap\u00f6tik ticarile\u015fmeye yakla\u015f\u0131rken, \u015firket d\u00fcnya \u00e7ap\u0131nda milyonlarca hastan\u0131n tedavi paradigmalar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilir.<\/p> <p>\u015eirketin \u00f6zel ke\u015fif platformu \u015fimdiden \u00e7\u0131\u011f\u0131r a\u00e7an sonu\u00e7lar verdi ve \u00e7e\u015fitlilik konusundaki taahh\u00fctleri de ayn\u0131 derecede etkileyici - y\u00f6netim kurulunun neredeyse %50'si kad\u0131n ve \u00e7al\u0131\u015fanlar\u0131n %65'i az temsil edilen etnik gruplardan olu\u015fuyor.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda Protagonist, ayn\u0131 anda iki farkl\u0131 ilac\u0131n FDA incelemesinden ge\u00e7ti\u011fi ve 2028'e kadar ek finansman olmadan faaliyet g\u00f6sterebilecek kadar nakit bulunduran birka\u00e7 biyoteknoloji \u015firketinden biri oldu. Bu finansal istikrar, tipik olarak nakit yakan biyoteknoloji sekt\u00f6r\u00fcnde neredeyse e\u015fi benzeri olmayan bir durumdur.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Giri\u015f Stratejisi<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Protagonist Therapeutics (PTGX) hisseleri <strong>hisse ba\u015f\u0131na $57.48<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Hisse senedi inan\u0131lmaz bir yolculuk ge\u00e7irdi, Mart 2025&#8217;te t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi olan $59.76&#8217;ya ula\u015ft\u0131 ve y\u0131l boyunca g\u00fc\u00e7l\u00fc momentumunu korudu.<\/p>\n<p><strong>Takviminize not edin: 6 Kas\u0131m 2025<\/strong>, PTGX yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kesinlikle kritik bir tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu a\u00e7\u0131klamalar hisse senedini \u00f6nemli \u00f6l\u00e7\u00fcde hareket ettirdi.<\/p>\n<h3>FDA Kararlar\u0131n\u0131n PTGX Hisselerine Etkisi<\/h3>\n<p>Son d\u00fczenleyici tetikleyicilere bakt\u0131\u011f\u0131m\u0131zda net bir desen g\u00f6r\u00fcyoruz:<\/p>\n<ul>\n<li><strong>Temmuz 2025<\/strong>: \u0130cotrokinra i\u00e7in NDA ba\u015fvurusu &#8211; sonraki hafta hisse %8 artt\u0131<\/li>\n<li><strong>Haziran 2025<\/strong>: Rusfertide Faz 3 verilerinin ASCO sunumu &#8211; an\u0131nda %12 y\u00fckseli\u015f<\/li>\n<li><strong>Mart 2025<\/strong>: \u00c7\u0131\u011f\u0131r A\u00e7an Terapi tan\u0131m\u0131 &#8211; iki hafta i\u00e7inde %15 s\u0131\u00e7rama<\/li>\n<li><strong>\u015eubat 2025<\/strong>: 4. \u00e7eyrek kazan\u00e7lar\u0131 beklentilerin \u00fczerinde &#8211; istikrarl\u0131 %6 de\u011fer art\u0131\u015f\u0131<\/li>\n<li><strong>Kas\u0131m 2024<\/strong>: Takeda ortakl\u0131k duyurusu &#8211; tek g\u00fcnde %18 s\u0131\u00e7rama<\/li>\n<li><strong>A\u011fustos 2024<\/strong>: Pozitif Faz 2b sonu\u00e7lar\u0131 &#8211; ay boyunca kademeli %22 art\u0131\u015f<\/li>\n<\/ul>\n<p>Desen a\u00e7\u0131k: d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 PTGX hissedarlar\u0131 i\u00e7in patlay\u0131c\u0131 b\u00fcy\u00fcme f\u0131rsatlar\u0131 yarat\u0131yor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h2>\n<p>Protagonist hisseleri son alt\u0131 ayda etkileyici getiriler sa\u011flad\u0131:<\/p>\n<p><strong>Mart<\/strong>: $59.76 (\u00c7\u0131\u011f\u0131r A\u00e7an Terapi haberi sonras\u0131 t\u00fcm zamanlar\u0131n en y\u00fcksek seviyesi)<br \/> <strong>Nisan<\/strong>: $54.20 (kar realizasyonu d\u00f6nemi)<br \/> <strong>May\u0131s<\/strong>: $51.80 (piyasa konsolidasyonu)<br \/> <strong>Haziran<\/strong>: $58.90 (ASCO veri a\u00e7\u0131klamas\u0131 sonras\u0131 y\u00fckseli\u015f)<br \/> <strong>Temmuz<\/strong>: $56.40 (NDA ba\u015fvurusu sonras\u0131 so\u011fuma)<br \/> <strong>A\u011fustos<\/strong>: $57.48 (mevcut istikrar)<\/p>\n<p>Bu, Mart zirvesinden <strong>% -3.8<\/strong> d\u00fc\u015f\u00fc\u015f\u00fc temsil ediyor ancak tipik biyoteknoloji volatilitesi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda hala dikkat \u00e7ekici bir dayan\u0131kl\u0131l\u0131k g\u00f6steriyor. Hisse senedi d\u00fczeltmelerden toparlanma yetene\u011fini kan\u0131tlad\u0131 ve bu da hem k\u0131sa vadeli yat\u0131r\u0131mc\u0131lar hem de uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in cazip hale getiriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik deneme ilerlemesine dayanarak, beklenenler \u015funlar:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: $65-75 aral\u0131\u011f\u0131 (FDA kararlar\u0131na ba\u011fl\u0131) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> <strong>2026<\/strong>: $85-100 (potansiyel ticarile\u015fmenin ilk tam y\u0131l\u0131)<br \/> <strong>2028<\/strong>: $120-150 (her iki ilac\u0131n da yerle\u015fik piyasa varl\u0131\u011f\u0131)<br \/> <strong>2030<\/strong>: $180-220+ (pipeline geni\u015flemesi ve uluslararas\u0131 b\u00fcy\u00fcme)<\/p>\n<p>Karar net: PTGX \u015fu anda biyoteknoloji alan\u0131ndaki en cazip al\u0131m f\u0131rsatlar\u0131ndan biri. \u0130ki potansiyel blockbuster ilac\u0131n onaya yakla\u015fmas\u0131 ve nakit pozisyonunun seyrelme riskini ortadan kald\u0131rmas\u0131, k\u0131sa vadeli volatilitenin \u00e7ok \u00f6tesinde bir yukar\u0131 potansiyel sunuyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>FDA reddi riski<\/strong>: Her iki ila\u00e7 da d\u00fczenleyici engellerle kar\u015f\u0131la\u015fabilir<\/li>\n<li><strong>Klinik deneme aksakl\u0131klar\u0131<\/strong>: Beklenmedik g\u00fcvenlik sorunlar\u0131 ortaya \u00e7\u0131kabilir<\/li>\n<li><strong>Rekabet<\/strong>: Benzer tedaviler geli\u015ftiren b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li>\n<li><strong>Piyasa volatilitesi<\/strong>: Biyoteknoloji sekt\u00f6r\u00fc dramatik dalgalanmalarla bilinir<\/li>\n<li><strong>Uygulama riski<\/strong>: Onay sonras\u0131 ticarile\u015ftirme zorluklar\u0131<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>\u00c7ift NDA s\u00fcreci<\/strong>: \u0130ki ila\u00e7 ayn\u0131 anda onaya yakla\u015f\u0131yor<\/li>\n<li><strong>\u00c7\u0131\u011f\u0131r A\u00e7an stat\u00fc<\/strong>: Rusfertide \u00f6zel FDA tan\u0131m\u0131na sahip<\/li>\n<li><strong>Nakit g\u00fcvenli\u011fi<\/strong>: 673 milyon dolar finansman endi\u015felerini ortadan kald\u0131r\u0131yor<\/li>\n<li><strong>B\u00fcy\u00fck ila\u00e7 ortakl\u0131klar\u0131<\/strong>: Takeda ve J&amp;J onay sa\u011fl\u0131yor<\/li>\n<li><strong>Piyasa talebi<\/strong>: Her iki durum da kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7lar\u0131 temsil ediyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Rahat oldu\u011funuz bir pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fc ile ba\u015flay\u0131n &#8211; hatta 5-10 hisse<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: $55 alt\u0131ndaki d\u00fc\u015f\u00fc\u015flerde pozisyonunuza ekleyin<\/li>\n<li><strong>Uyar\u0131lar kurun<\/strong>: 6 Kas\u0131m kazan\u00e7lar\u0131n\u0131 ve FDA duyurular\u0131n\u0131 takip edin<\/li>\n<li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu 2-3 y\u0131ll\u0131k bir yat\u0131r\u0131m hikayesi, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li>\n<li><strong>Esprili yakla\u015f\u0131m<\/strong>: &#8220;PTGX ticareti bir t\u0131bbi drama izlemek gibi &#8211; bolca gerilim var ama sezon finali muhte\u015fem olabilir!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>PTGX&#8217;i detayl\u0131ca ara\u015ft\u0131r\u0131n<\/td>\n<td>\u015eirketin pipeline&#8217;\u0131n\u0131 ve risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015finizi verin<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 takip edin<\/td>\n<td>Anahtar seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Biyoteknoloji yat\u0131r\u0131mlar\u0131na ad\u0131m atmak isteyenler i\u00e7in Pocket Option, yeni ba\u015flayanlar i\u00e7in ideal k\u0131lan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece $5 minimum depozito<\/strong> &#8211; \u00d6\u011frenirken neredeyse risksiz ba\u015flayabilirsiniz<\/li>\n<li><strong>\u015eim\u015fek h\u0131z\u0131nda do\u011frulama<\/strong> &#8211; Tek bir belge y\u00fckleyin ve dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Karlar\u0131n\u0131z\u0131 birden fazla \u00f6deme y\u00f6ntemiyle \u00e7ekin<\/li>\n<li><strong>Kullan\u0131c\u0131 dostu platform<\/strong> &#8211; Hisse senedi ticaretine yeni ba\u015flayanlar i\u00e7in m\u00fckemmel<\/li>\n<\/ul>\n<p>Platformun d\u00fc\u015f\u00fck giri\u015f engeli, Protagonist Therapeutics ile stratejileri test etmek ve daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce denemek i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Protagonist: Biyoteknolojinin Y\u00fckselen Y\u0131ld\u0131z\u0131<\/h2>\n<p>Protagonist Therapeutics, en heyecan verici orta \u00f6l\u00e7ekli biyoteknoloji \u015firketlerinden biri olarak konumland\u0131. \u0130ki yeni peptid terap\u00f6tik ticarile\u015fmeye yakla\u015f\u0131rken, \u015firket d\u00fcnya \u00e7ap\u0131nda milyonlarca hastan\u0131n tedavi paradigmalar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcrebilir.<\/p>\n<p>\u015eirketin \u00f6zel ke\u015fif platformu \u015fimdiden \u00e7\u0131\u011f\u0131r a\u00e7an sonu\u00e7lar verdi ve \u00e7e\u015fitlilik konusundaki taahh\u00fctleri de ayn\u0131 derecede etkileyici &#8211; y\u00f6netim kurulunun neredeyse %50&#8217;si kad\u0131n ve \u00e7al\u0131\u015fanlar\u0131n %65&#8217;i az temsil edilen etnik gruplardan olu\u015fuyor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda Protagonist, ayn\u0131 anda iki farkl\u0131 ilac\u0131n FDA incelemesinden ge\u00e7ti\u011fi ve 2028&#8217;e kadar ek finansman olmadan faaliyet g\u00f6sterebilecek kadar nakit bulunduran birka\u00e7 biyoteknoloji \u015firketinden biri oldu. Bu finansal istikrar, tipik olarak nakit yakan biyoteknoloji sekt\u00f6r\u00fcnde neredeyse e\u015fi benzeri olmayan bir durumdur.<\/p>\n"},"faq":[{"question":"Protagonist Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Protagonist Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"PTGX hisseleri i\u00e7in minimum yat\u0131r\u0131m miktar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m miktar\u0131 se\u00e7ti\u011finiz platforma ba\u011fl\u0131d\u0131r ancak genellikle 5-10 hisse ile k\u00fc\u00e7\u00fck bir pozisyon a\u00e7abilirsiniz."},{"question":"PTGX hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"FDA onay kararlar\u0131, klinik deneme sonu\u00e7lar\u0131, ortakl\u0131k duyurular\u0131 ve genel piyasa ko\u015fullar\u0131 PTGX hisselerinin fiyat\u0131n\u0131 etkileyen ba\u015fl\u0131ca fakt\u00f6rlerdir."},{"question":"PTGX hisseleri uzun vadeli yat\u0131r\u0131m i\u00e7in uygun mu?","answer":"Evet, PTGX biyoteknoloji alan\u0131nda b\u00fcy\u00fcme potansiyeli y\u00fcksek bir \u015firket olup, 2-3 y\u0131l ve \u00fczeri yat\u0131r\u0131m i\u00e7in uygundur."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"FDA kararlar\u0131, klinik deneme geli\u015fmeleri, piyasa volatilitesi ve \u015firketin finansal durumu gibi riskleri g\u00f6z \u00f6n\u00fcnde bulundurmal\u0131s\u0131n\u0131z."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Protagonist Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Protagonist Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden al\u0131m yapabilirsiniz."},{"question":"PTGX hisseleri i\u00e7in minimum yat\u0131r\u0131m miktar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m miktar\u0131 se\u00e7ti\u011finiz platforma ba\u011fl\u0131d\u0131r ancak genellikle 5-10 hisse ile k\u00fc\u00e7\u00fck bir pozisyon a\u00e7abilirsiniz."},{"question":"PTGX hisselerinin fiyat\u0131n\u0131 etkileyen ana fakt\u00f6rler nelerdir?","answer":"FDA onay kararlar\u0131, klinik deneme sonu\u00e7lar\u0131, ortakl\u0131k duyurular\u0131 ve genel piyasa ko\u015fullar\u0131 PTGX hisselerinin fiyat\u0131n\u0131 etkileyen ba\u015fl\u0131ca fakt\u00f6rlerdir."},{"question":"PTGX hisseleri uzun vadeli yat\u0131r\u0131m i\u00e7in uygun mu?","answer":"Evet, PTGX biyoteknoloji alan\u0131nda b\u00fcy\u00fcme potansiyeli y\u00fcksek bir \u015firket olup, 2-3 y\u0131l ve \u00fczeri yat\u0131r\u0131m i\u00e7in uygundur."},{"question":"Yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"FDA kararlar\u0131, klinik deneme geli\u015fmeleri, piyasa volatilitesi ve \u015firketin finansal durumu gibi riskleri g\u00f6z \u00f6n\u00fcnde bulundurmal\u0131s\u0131n\u0131z."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T16:51:18+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T16:51:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\",\"name\":\"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"datePublished\":\"2025-08-25T16:51:18+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T16:51:18+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T16:51:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/","name":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","datePublished":"2025-08-25T16:51:18+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals10.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Protagonist Therapeutics, Inc. (PTGX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Protagonist Therapeutics, Inc. (PTGX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":349271,"slug":"how-to-buy-protagonist-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Protagonist Therapeutics, Inc. (PTGX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Protagonist Therapeutics, Inc. (PTGX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":349270,"slug":"how-to-buy-protagonist-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Protagonist Therapeutics, Inc. (PTGX) - Investimento em a\u00e7\u00f5es da Protagonist Therapeutics, Inc. (PTGX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-protagonist-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=349268"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/349268\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334072"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=349268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=349268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=349268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}